Industrial Leads for the Week of December 29, 2025

New Jersey

Celltrion USA is planning to accumulate and develop Eli Lilly and Co.’s biopharmaceutical plant in Branchburg. Scope of the estimated $630-million challenge is being developed however may embrace building and modification of constructing house; modification of manufacturing traces; and buy and set up of automation, storage, dealing with, formulation, filling and packaging tools and methods. The enlargement will improve drug substance and drug product manufacturing capability to 135,000 liters per 12 months. Plant acquisition is predicted by the top of 2025. Roughly 50% of manufacturing traces will proceed manufacturing of Eli Lilly biologics on a contract foundation. Celltrion expects to start manufacturing of its personal line of antibody-based biologics for autoimmune and most cancers therapies on the website in 2027. Celltrion USA, One Evertrust Plaza, Suite 1207, Jersey Metropolis, NJ 07302. IR#NJ250905

Virginia

AstraZeneca is planning to assemble an energetic pharmaceutical elements and prescribed drugs manufacturing plant on a 462-acre website in Albemarle County. Challenge scope consists of building of a number of buildings with cleanrooms; and buy and set up of stainless-steel tanks and piping, bioreactors, fume hoods and moist laboratory, filtration, testing, sterilization, filling, ending, labeling, packaging and chilly storage tools. A building schedule is being developed; the challenge is predicted to be operational in 2029 or 2030. The plant can be used to provide small molecules, peptides, oligonucleotides and antibody drug conjugates to provide oral drug substances for weight and metabolic administration, mixture small molecule merchandise and oncology indication therapies. AstraZeneca, 1 Medimmune Approach, Gaithersburg, MD 20878. IR#VA251001

Wyoming

BWX Applied sciences Inc. is planning to assemble a tri-structural isotropic nuclear particle gas manufacturing facility in Gillette. The challenge’s scope consists of building of constructing house and tools foundations; in addition to buy and set up of thermal-activated reactors, and dissolving, mixing, cooling, dispersing, assortment, cleansing, rinsing, fluidized-bed chemical vapor deposition, isostatic urgent, pelletizing, encasing and coating tools and methods. BWX estimates building will start within the fourth quarter of 2026. BWX Applied sciences, Inc. Nuclear Operations Group, 800 Foremost St., Lynchburg, VA 24504. IR#WY251001